VivoSeq
Other

PDL-1

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

PDL-1 is an early-stage landscape with 0 programs across 1 company. The most active players are Effector Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Effector Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Recruiting2 · 40%
Completed1 · 20%
Unknown status1 · 20%
Terminated1 · 20%

Clinical Trials

Trial Activity

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Recruiting·SSichuan University·Phase 1·NCT06348797·28 enrolled
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Completed·EEffector Therapeutics·Phase 2·NCT03616834·39 enrolled
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC
Unknown status·ZZhongda Hospital·N/A·NCT05332496·220 enrolled
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT06364917·24 enrolled
Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
Terminated·OOncovir, Inc.·Phase 1/2·NCT03721679·7 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)